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Abstract
Background: Acute kidney injury (AKI) is a prominent problem in hospitalized patients and associated with
increased morbidity and mortality. Clinical medicine is currently hampered by the lack of accurate and early
biomarkers for diagnosis of AKI and the evaluation of the severity of the disease.
In 2010, we established a multivariate peptide marker pattern consisting of 20 naturally occurring urinary peptides
to screen patients for early signs of renal failure. The current study now aims to evaluate if, in a different study
population and potentially various AKI causes, AKI can be detected early and accurately by proteome analysis.
Methods: Urine samples from 60 patients who developed AKI after cardiac surgery were analyzed by capillary
electrophoresis-mass spectrometry (CE-MS). The obtained peptide profiles were screened by the AKI peptide marker
panel for early signs of AKI. Accuracy of the proteomic model in this patient collective was compared to that based
on urinary neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule-1 (KIM-1) ELISA levels. Sixty
patients who did not develop AKI served as negative controls.
Results: From the 120 patients, 110 were successfully analyzed by CE-MS (59 with AKI, 51 controls). Application of
the AKI panel demonstrated an AUC in receiver operating characteristics (ROC) analysis of 0.81 (95 % confidence
interval: 0.72–0.88). Compared to the proteomic model, ROC analysis revealed poorer classification accuracy of NGAL
and KIM-1 with the respective AUC values being outside the statistical significant range (0.63 for NGAL and 0.57 for
KIM-1).
Conclusions: This study gives further proof for the general applicability of our proteomic multimarker model for early
and accurate prediction of AKI irrespective of its underlying disease cause.
Keywords: Acute kidney injury, Cardiac surgery, Urinary peptide pattern, Prediction, Test validation
Background
Acute kidney injury (AKI) is a common complication
among hospitalized patients occurring in 5 % of all hos-
pital and 35 % of intensive care unit (ICU) admissions
[1, 2]. Moreover, AKI considerably increases morbidity,
mortality and health care expenditures, independently of
other comorbidities [1]. Patients undergoing cardiac sur-
gery have a highly increased risk to develop postopera-
tive AKI compared to other hospitalized patients. This is
attributed to procedure-related factors such as the use of
extracorporeal circulation or aortal clamping time,
potentially leading to exacerbated in situ hypoxic con-
ditions, and resulting in up to 30 % incidences of
postoperative AKI [2, 3]. Moreover, occurrence of
AKI plays an important role for the postoperative
outcome, being associated with high mortality [4].
Therefore, detection of AKI is of major interest espe-
cially for patients undergoing cardiac surgery and
other extensive surgery regimes.
The recent Acute Kidney Injury Network (AKIN) def-
inition and classification of AKI incorporates serum cre-
atinine and urine output as markers to diagnose and
stage AKI [5]. However, these markers neither permit
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early detection of AKI nor indicate the underlying
pathophysiological mechanisms.
Although no effective therapy of AKI is currently
available, its earliest possible diagnosis seems to be ad-
vantageous since postoperative AKI is associated with
mortality after cardiac surgery [3].
Proteomics is the part of omics technologies that most
specifically displays an individual’s physiological state.
The proteome is encoded by the genome in alteration to
external signals and modulants, and is further diversified
by posttranslational modifications and proteolytic pro-
cessing. Compared to blood, the urine proteome is less
complex and to a lesser extent subject to further dy-
namic alterations due to a low proteolytic activity in situ
making it more stable ex vivo [6–8]. The proteomic con-
tent of urine arises from the secretion and shedding of
proteins from the kidney endothelium, release of kidney
epithelial exosomes inside the kidney, and also glomeru-
lar filtration and endosomal-exosomal passage of blood-
circulating proteins. Capillary electrophoresis-mass spec-
trometry (CE-MS) has emerged in recent years as a
hybrid technology using capillary electrophoresis (CE)
instead of liquid chromatography for protein separation
before mass spectrometry (MS) [9]. Without the need of
a sieving matrix, CE-MS enables sensitive (1 fmol) and
fast (approximately 1 h) analysis of the low molecular
weight proteome in the range of 0.8–20 kDa as demon-
strated in a large number of studies as recently reviewed
by Pejchinovski et al. [10].
In the last years, several urinary compounds (e.g.,
neutrophil gelatinase-associated lipocalin [NGAL]) were
shown to be able to detect AKI earlier compared to in-
crease of serum creatinine according to the currently
used definition and classification of AKI [1, 4]. However,
these single markers are related to a specific patho-
physiological process of AKI, e.g., NGAL to ischemic or
toxic tubular damage [5, 11, 12]. Since reasons for acute
renal failure in clinical practice are very heterogeneous,
this may explain conflicting results in the literature con-
cerning those single-marker tests for early detection of
AKI. However, those biomarkers were shown to have the
capacity to detect early AKI and also the predictive
capacity for extrarenal postoperative complications, e.g.,
nonocclusive mesenterial ischemia (NOMI) or death
[13]. We therefore compared the predictive capacity of
proteome analysis for AKI with NGAL and kidney injury
molecule-1 (KIM-1), and we evaluated whether extrare-
nal complications could have influenced the detection of
AKI. Therefore, a method of detecting AKI independent
of the underlying pathogenesis or other extrarenal oc-
curring complications seems promising. In our previ-
ously published pilot study [14], we used CE-MS to
establish a urinary peptide test predictive for AKI.
Twenty polypeptides from the urinary proteome were
selected as a panel of markers to generate a classifier.
The marker pattern was able to detect early AKI and
was superior in prediction of AKI compared to serum
cystatin C, urinary kidney injury molecule-1 (KIM-1),
interleukin-18 (IL-18) or NGAL.
The current study has the following objectives: first,
the validation of the urine peptide marker panel in a dif-
ferent clinical setting to prove its prognostic accuracy
for AKI independently of the underlying pathogenesis.
Second, the comparison of the urine peptide marker
panel’s classification performance in this group of post-
cardiac surgery patients to that based on urinary NGAL
and KIM-1 levels. Third, the evaluation of the urine pep-
tide marker panels predictive capacity with respect to
the severity of AKI, and finally association of proteomic
classification to the AKI-associated complications,
NOMI, and death.
Methods
Patients and samples
For this study, samples of 120 patients were retrospect-
ively selected from a large prospective cohort study
population of 865 patients undergoing cardiac surgery
aiming to identify prognostic markers for postoperative
complications. This prospective study and the included
population is described in detail in Speer et al. [15] and
Klingele et al. [16]. Within this study, AKI was defined
according to the Acute Kidney Injury Network (AKIN)
criteria [5]. Written informed consent had been obtained
from all patients. Ethical approval was obtained from
the local ethics committee (Landesärztekammer des
Saarlandes; Ref. ID: 199/09) and the study conformed
to the standards set by the Declaration of Helsinki.
Since the study took place 2 years after discharge of
patients, clinical data and outcome were known, espe-
cially whether or not AKI occurred, and also included
knowledge about the severity of AKI and AKIN class.
Moreover, since this validation study aimed to investi-
gate whether our previously published proteome test
can accurately predict AKI in a clinical setting, the
sole selection criterion was to obtain a cohort of 60
patients with AKI being balanced in the distribution
of the different AKIN classes. For this reason, we ran-
domly selected 25 patients out of all patients with
AKIN 1. In the same way 15 patients with AKIN 2
and 20 patients with AKIN 3 were chosen. From the
patient pool without AKI we randomly picked 60 pa-
tients as a control group.
For preoperative analysis, blood was drawn from the
central venous catheter and urine samples were collected
from the urinary catheter both directly before the inter-
vention. The surgical procedures were generally carried
out during the day. The next morning at 6:00 am,
between 12 to 18 hours after surgery, postoperative
Metzger et al. Critical Care  (2016) 20:157 Page 2 of 9
samplings of blood and urine were performed. Urine
samples were transported on ice, aliquoted in polypro-
pylene tubes (Sarstedt AG, Nümbrecht, Germany) and
stored at –80 °C for subsequent analysis.
Proteome analysis was carried out by Mosaiques
Diagnostics GmbH in Hannover as previously published
[14]. Analysis took place 2 years after cardiac surgery.
Samples alone without clinical information related to the
patients were sent, and the proteome analyses were
therefore performed in a blinded manner. Subsequent to
communicating the results of the proteome analyses to
the physicians at the Saarland University Hospital, sam-
ples were all unblinded and all clinical data necessary for
further evaluation (e.g., AKI or no AKI) were provided.
Sample preparation
The urine samples were prepared as previously de-
scribed by removing large proteins (>20 kDa), urea, elec-
trolytes and salts, and by enriching polypeptides [17].
Briefly, 700 μL of urine were defrosted with the addition
of 0.1 % PMSF saturated in ethanol and diluted with
700 μL of a solution containing 2 M urea, 0.1 M NaCl,
10 mM NH4OH and 0.02 % SDS. The mixture was then
filtered through a 20 kDa MW cut-off ultracentrifuga-
tion filter device (Sartorius Stedim UK Ltd, Stonehouse,
United Kingdom) at 3000 × g for 1 hour at 4 °C. A
volume of 1.1 mL of the resulting filtrate was loaded
onto a pre-equilibrated PD-10 desalting column (GE
Healthcare, Stockholm, Sweden) and eluted using 0.01 %
aqueous NH4OH. The eluate was subsequently freeze-
dried and stored at 4 °C prior to being resuspended in
HPLC-grade water to a final protein concentration of
2 mg/mL for CE-MS analysis.
CE-MS analysis
CE-MS analysis was performed as described by Metzger
et al. [14] using a P/ACE MDQ capillary electrophoresis
system (Beckman Coulter, Fullerton, CA, USA) on line
coupled to a MicroTOF MS (Bruker Daltonic, Bremen,
Germany). Samples were injected hydrodynamically at
2.0 psi for 99 sec (ca. 250 nL) and separation of peptides
was achieved by reverse polarity at 25 kV for the first
30 min, and with increasing pressure (up to 0.5 psi) for
another 34 min. The cartridge temperature was main-
tained at 25 °C. Running buffer contained 79:20:1 (v/v)
MilliQ water, acetonitrile, and formic acid. Sheath liquid
consisted of 30 % 2-propanol and 0.4 % formic acid in
MilliQ water. The ESI sprayer (Agilent Technologies,
Palo Alto, CA, USA) was grounded, and the ion spray
interface potential was set between -4 and -4.5 kV. Spec-
tra were accumulated every 3 seconds over a range of
mass-to-charge ratios from 50 to 3000. Details on accur-
acy, precision, selectivity, sensitivity, reproducibility, and
stability of the CE-MS method have been previously re-
ported [8, 17–19].
Proteomic data processing and sample classification
Mass spectral ion peaks with a charge >1 and a
signal-to-noise ratio >4 detectable in at least three
consecutive spectra and assignable to the same pep-
tide entity were deconvoluted into single masses using
the MosaiquesVisu software [20, 21]. CE migration
time and ion signal intensity were normalized using
internal peptides with high abundance and low mass
deviation as calibrants [22]. Sample-specific peptide
lists were deposited in a SQL database for subsequent
analysis.
Test results of the samples were classified into the cat-
egories ‘AKI’ and ‘non-AKI’ by the urinary AKI predict-
ive peptide marker panel, the classification algorithm
and the cut-off point at 0.02. The later was established
in our recent pilot study as the classification score with
the highest average in sensitivity and specificity on a rep-
resentative ICU training set [14].
Immunoassays and laboratory tests
NGAL and KIM-1 were measured in urine samples
using human-specific ELISA assays (Enzo Life Sciences,
Exeter, UK; kits #BPD-KIT-036 and #ADI-900-226-0001
respectively) and were carried out according to the man-
ufacturer’s instructions. Modifications of recommended
assay conditions included higher dilutions for both kits
to cover a higher than expected quantity range in neat
urine.
Statistical methods
Estimates of sensitivity and specificity for the AKI predict-
ive peptide marker model were calculated by tabulating
the number of correctly classified samples. Confidence in-
tervals (95 % CI) for sensitivity and specificity were based
on exact binomial calculations and were carried out
in MedCalc 12.7.7.0 (MedCalc Software, Mariakerke,
Belgium) as were the receiver operating characteristic
(ROC) plots. The area under the ROC curve (AUC) was
evaluated, as it provides a single measure of overall accur-
acy independent upon a particular threshold [23].
Results
The selected 60 AKI case and 60 non-AKI controls were
analyzed by CE-MS to obtain their proteomic profiles in
the mass range of 0.8–20 kDa. One AKI case and nine
non-AKI control samples failed to fulfill the quality con-
trol criteria for the CE-MS profiles due to the presence
of considerable amounts of polymers in the catheter
urine and were therefore excluded from further analysis.
An overview of the patient’s demographic and clinical
data in the two groups relevant to this study is presented
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in Table 1. Since the occurrence of AKI was the sole cri-
terion for selection, AKI patients and those without AKI
are significantly different with respect to age, preoperative
renal function or the occurrence of severe postoperative
complications such as NOMI or death. A total of 25 % of
patients with AKI required renal replacement therapy.
All CE-MS profiles that passed the quality control
were classified using the AKI predictive peptide marker
model as described previously [14]. CE-MS characteris-
tics and sequence information of the 20 peptides in-
cluded in this peptide marker model are presented in
Additional file 1: Table S1.
Classification performance of the AKI predictive
model for the study cohort of cardiac patients was evalu-
ated by ROC analysis [23]. As shown in Fig. 1a, the AKI
peptide marker model enabled prediction of AKI with
an AUC value of 0.81 and a range within the 95 % confi-
dence interval (CI) from 0.72 to 0.88, which is highly sig-
nificant (p < 0.0001). At the predetermined cut-off of
0.02, the sensitivity and specificity of the AKI peptide
marker model on this post-cardiac surgery patient co-
hort was 64.4 and 88.2 %, respectively. In comparison to
the AKI peptide marker model, the proposed single AKI
markers NGAL and KIM-1 as determined by ELISA only
showed low classification accuracy on the patient set
with AUC values of 0.63 (95 % CI: 0.53–0.72; p = 0.02)
for NGAL and 0.57 (95 % CI: 0.47–0.67; p = 0.22) for
KIM-1 (Fig. 1b). The AUC of the ROC curve of the AKI
peptide marker model was significantly superior to both
NGAL (p = 0.0032) and KIM-1 (p = 0.0034).
We tested if urine proteomics would be predictive
for other postoperative complications such as NOMI
or death (Fig. 2). NGAL and our urine peptide
marker model showed comparable predictive capacity
for NOMI and death. Interestingly, both NGAL and
our urine peptide marker model were at least as pre-
dictive for postoperative mortality as the 18 factors
comprising EuroSCORE II being developed specifically
for prediction of the 30-day mortality rate after car-
diac surgery [24].
Patients with postoperative AKI had significantly more
additional serious complications. Therefore, we subdi-
vided our cohort in three groups: no AKI and AKI, both
without any other complication, and patients with AKI
and with NOMI and/or death (Fig. 3). NGAL differenti-
ated well between patients without AKI and those with
AKI and NOMI or death. However, patients suffering
only from AKI showed similar NGAL levels than those
Table 1 Clinical and demographic data of AKI cases and non-AKI controls of post-cardiac surgery patients
Parameter AKI Non-AKI p
Patients/samples (n/n) 59/59 51/51
Age (years)† 65 (45–77) 60 (24–77) 0.03
Gender (female/male) 13/46 16/35 0.29
EuroSCORE II** (points)† 6.82 (0.86–28.34) 5.99 (0.67–21.93) 0.89
Body mass index† 30.7 (19.9–47.3) 30.8 (17.3–41.4) 0.86
S-creatinine at baseline (mg/dL)† 1.1 (0.6–1.9) 0.9 (0.6–1.3) <0.001
Estimated glomerular filtration rate at baseline (mL/h/1.73 m2)‡,† 73 (37–110) 92 (56–132) <0.001
Diabetes (%) 29 18 0.19
OP time (min)† 214 (105–390) 211 (109–651) 0.6
Time of cardiopulmonary bypass (min)† 109 (48–243) 103 (34–177) 0.81
Clamping time (min)† 66 (17–184) 67 (26–125) 0.77
Endpoints:
NOMI (%)ǁ 29 2 <0.001
Death (%)ǁ 17 0 0.002
AKI staging (n):
0 0 51
1 25 0
2 14 0
3 20 (15 w/ hemodialysis) 0
AKI acute kidney injury, NOMI nonocclusive mesenteric ischemia,
**Thoracic Surgeons Risk Score to predict mortality after thoracic surgery, for calculation see: http://www.euroscore.org/
‡According to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)
†Given as mean (range)
ǁ7 % of AKI patients with composite endpoint
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without AKI. In contrast, our urine peptide marker model
differentiated patients without AKI from both AKI pa-
tients with as well as without NOMI and/or death.
In order to evaluate whether the classification scores
were associated with the severity of AKI according the
AKIN criteria [5], a nonparametric rank sum test with
the AKI stages as ordinal data was applied to the classifi-
cation of patient samples by the proteomic test. As
shown in the box-and-whisker plot of Fig. 4, significant
rank sum differences were observed for patients without
AKI (stage 0) in comparison to the other AKI stages and
for stage 1 in comparison to stage 2 and 3. However, our
results show overlaps especially for AKIN 2 and 3.
Therefore, the classification scores of our AKI peptide
marker model allow an early and accurate detection of
AKI. Nevertheless, a reliable prediction of severity of
AKI was not possible in all patients.
Discussion
This study confirms the prognostic potential of our re-
cently described urinary biomarker panel for the early
detection of AKI [14]. In this respect, the performance
of the proteomic classifier was superior to the single
ELISA markers NGAL and KIM-1 in our validation pa-
tient cohort consisting of patients after cardiac surgery.
This is in line with several studies showing conflicting
results for the diagnostic performance of these markers.
On the one hand, these single molecules were shown as
potential biomarkers for AKI [25, 26]. On the other
hand, in several other studies they failed to demonstrate
any true benefit [14, 27–30]. A possible explanation for
these opposing results would be that AKI represents a
final result of many and divergent pathophysiological
processes and causes, but that its diagnosis is uniformly
based on increased serum creatinine and/or reduced
urine output. This may explain why NGAL recognizes
well and early AKI in cases of mainly tubular damage
[11, 12] but less well in case of other pathophysiological
mechanisms of AKI. Thus, detection of AKI by a panel
of different peptides as proposed in our proteomic test
seems to be more reliable covering numerous underlying
pathological mechanisms.
Fig. 1 ROC characteristics for prediction of AKI in post-cardiac surgery patients (a) by the AKI peptide marker panel and (b) by the single markers
NGAL and KIM-1. Whereas for the AKI peptide marker panel the sensitivity and specificity was determined at the previously established cut-off,
these values were determined for NGAL and KIM-1 at the optimal cut-off according to the Youden index. AKI acute kidney injury, AUC area under
the ROC curve, KIM-1 kidney injury molecule-1, NGAL neutrophil gelatinase-associated lipocalin, ROC receiver operating characteristic
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Our results clearly demonstrate, that proteome ana-
lysis of the urine within 12 to 18 hours postoperatively
allows accurate detection of postoperative AKI. Since
AKI in this patient collective was induced by the surgical
procedure, the diagnostic performance of the proteomic
model was determined for AKI patients with a broad
range of the time intervals between sampling and clinical
diagnosis of AKI. AKI is defined by AKIN criteria [5].
Based on this definition, AKI can be clinically diagnosed
in case of oliguria and anuria. However, when urine out-
put remains unchanged, AKI only can be diagnosed and
classified by the rate of increased serum creatinine levels
within 48 hours [5]. This definition is in contrast to the
currently pursued therapeutic principle of an “early goal-
directed therapy”. Proteome analysis accelerates the
detection of AKI and would support this therapeutic
request. Our proteomic marker will meet these require-
ments of a rapid and reliable diagnosis of severe AKI re-
gardless of the underlying cause. Although our urine
peptide marker panel enabled accurate prediction of
AKI in patients after cardiac surgery, reliable prediction
of severity of AKI as expressed by the AKIN criteria was
not possible in all of the patients, especially for the dis-
crimination between AKIN 2 and 3. This could partially
be explained by the small number of patients. Beyond
that, the primary intention for investigating the urine
proteome was the detection of AKI in general. The 20-
peptide marker panel was developed for this purpose
[14]. Therefore, in this study we tested for the first time
if our proteomic test would also allow prediction of AKI
severity. Since the results suggest an association of our
classification scores with AKI severity, further develop-
ment of our proteomic classifier could be helpful to im-
prove the power of discrimination of AKIN classes. This
hypothesis will be tested in further studies with suffi-
ciently large study populations.
The complex causes and pathophysiological processes
resulting in clinical AKI are not fully understood so far.
Interestingly, many serious complications occur only in
patients who also developed AKI. This leads to the ques-
tion whether AKI is a cause for further complications or
whether there may be a common pathogenetic mechan-
ism, resulting in AKI and other complications. Since
NOMI and death were primary endpoints in the pro-
spective cohort study [15, 16] we used these clinical data
for the former raised question.
Patients with postoperative AKI had significantly more
other serious complications and our urine proteomic
test and also NGAL were predictive for these postopera-
tive complications, Therefore the predictive capacity for
death or NOMI could be partially explained by this coin-
cidence. However, when we assessed separately on com-
plications and combination of AKI, NOMI, and/or death
we could demonstrate that our test could well differenti-
ate between patients developing AKI and those who did
not. In contrast, NGAL was only able to do so in pa-
tients with AKI and NOMI. We hypothesized that simi-
lar pathophysiological mechanisms may trigger AKI and
NOMI resulting in a high coincidence. These patho-
physiological mechanisms result in tubular damage,
Fig. 2 Classification accuracy of the AKI peptide marker pattern and the other AKI predictive markers NGAL, KIM-1 and EuroSCORE II for the
AKI-associated endpoints nonocclusive mesenteric ischemia (NOMI) and death in comparative ROC analysis. Shown is a receiver operating
curve (ROC) comparison of the different prognostic markers for the endpoints NOMI (upper left panel) and death (upper right panel) and a
table summarizing the corresponding ROC-derived area under the curve (AUC) values of the different prognostic markers for these two
AKI-associated endpoints. AKI acute kidney injury, KIM-1 kidney injury molecule-1, NGAL neutrophil gelatinase-associated lipocalin
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explaining why NGAL detects these cases accurately.
Thus, the underlying pathophysiological causes of AKI
are different in patients who did not develop NOMI.
This also would explain why AKI in these patients was
not detected by NGAL, but with our urine peptide
marker panel.
In view of the complexity of AKI, a multifactorial diag-
nostic tool seems to be more reliable. Moreover, such a
differentiated approach could help to better understand
the complex pathophysiological processes of AKI and
other obviously related complications. However, poten-
tial limitations exist for such multidimensional prote-
omic tests as used in this study. These can arise from
the high inter-individual variability of the urinary prote-
ome and its dynamic nature under the influence of non-
renal factors such as biological variance. Moreover,
correcting for urinary dilution or removal of peptides
with specific properties, like those with affinity to albu-
min, during sample preparation might introduce to some
degree further analytical variability. However, in this
study measures were undertaken to keep these sources
of variability to a minimum. This includes:
1) Preparation of the urine sample under chaotropic
and denaturating conditions that are strong enough
to disrupt any protein-to-protein interaction before
the removal of high molecular compounds above 20
kDa [31].
2) Use of the flow-based sieving matrix-free capillary
electrophoresis for peptide separation and operation
of the CE-MS under highly acidic conditions (pH 2)
preventing adsorption of the peptides to the capillary
surface [31].
3) Normalization of the peptide’s amplitude signals to
29 highly abundant internal collagen peptides with
low variance in their amplitude signals and which are
unaffected by any known disease state to
compensate for differences in the dilution of
individual urine samples [22].
Fig. 3 Distribution of classification scores of the AKI marker pattern
(upper panel) and NGAL levels in ng/mL (lower panel) in AKI and
non-AKI patient subgroups showing either progression or lack of
nonocclusive mesenteric ischemia (NOMI) or death. A post hoc test
was performed for average rank differences between the different
subgroups (each with p < 0.05) after a significant result in the global
Kruskal-Wallis test (p < 0.0001). AKI acute kidney injury, NGAL neutrophil
gelatinase-associated lipocalin
Fig. 4 Box-and-whisker representation of classification factors for the
different AKI stages by the AKI peptide marker pattern. AKI acute
kidney injury
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Moreover, the peptide marker panel itself is well
balanced in its composition in respect to the inclu-
sion of peptide markers with increased or decreased
urinary levels during AKI progression making classifi-
cation independent from the overall peptide content
of the urine [14].
A limitation of CE-MS is its highly skilled operating
level and relative high operating costs making it imprac-
tical at first sight for close and cost-effective monitoring
of acute events in daily clinical practice. A transfer of
the peptide markers to the higher throughput, less ex-
pensive, and less skilled matrix-assisted laser desorption
ionization (MALDI)-MS technology is one way to solve
this problem [32]. However, since we could establish a
proteomic pattern of AKI a few days prior to its clinical
manifestation, a strategy where a urine sample will be
drawn routinely from the catheter bag a few hours after
cardiac surgery for immediate analysis by CE-MS dir-
ectly at the hospital site might also be a practical
strategy, as already is in place for other sophisticated
diagnostic systems like flow cytometry-based diagnostics,
in order to improve clinical management of post-cardiac
surgery patients at least in university hospitals and large
cardiac surgery reference centers.
Although this study confirms that our previously pub-
lished proteomic marker model detects AKI accurately,
the number of included patients is still relatively small.
The wide use of CE-MS in clinical practice is not yet
possible due to the aforementioned methodical and
technical aspects. Since the overall method from sample
preparation over CE-MS analysis to proteomic data pro-
cessing is rather time consuming (>24 hours) and of
high cost (approximately 300 to 800 euros per sample),
we could not test all 865 patients of the initial prospect-
ive study population. Based on a sample size calculation
with respect to the statistical power, we have thus in-
cluded 60 patients with AKI and an equal number of pa-
tients without AKI as a control group in this validation
study. Moreover, we initially did not intend to compare
any parameter other than AKI between these 120 pa-
tients. Thus, for the obvious coincidence of AKI with
NOMI and or death described above, we can give no
further explanation or examine this with respect to our
data.
Conclusions
The recent study provided evidence that the 20-peptide
marker panel originally established for AKI prediction in
ICU patients also allows accurate prediction of AKI in
the clinical setting of cardiac surgery. In this instance, it
is superior to the prediction based on urinary NGAL
and KIM-1 levels. In addition, the predictive perform-
ance for the AKI-associated endpoints, NOMI, and
death reached the same high level of accuracy as for
AKI. Although discrimination of higher AKIN classes
was not possible in all patients, our test allows predic-
tion of severe outcome (AKIN classes 2 and 3) in AKI.
Thus, our proteomic marker model for AKI prediction
may positively impact the management of ICU patients
helping to improve outcome in AKI.
Key messages
In patients undergoing elective cardiac surgery:
 Urine proteomic analysis allows accurate and early
detection of AKI, even before AKI can be diagnosed
by increase of creatinine as described in the current
definition for AKI.
 The predictive capacity for postoperative AKI of our
20-peptide marker pattern is superior compared to
the diagnosis based on urinary levels of NGAL and
KIM-1. The same high level of predictive performance
of the proteomic test as for AKI was reached for the
AKI-associated endpoints, NOMI, and death.
 Since AKI is a common endpoint of different
pathological pathways, a multifactorial diagnostic
tool such as the 20-peptide marker pattern seems
to be more reliable for diagnosis of AKI than
diagnostic tests based on single AKI markers.
Additional file
Additional file 1: Table S1. Sequence information for the 20 urinary
peptides included in the AKI peptide marker pattern. (PDF 10804 kb)
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